glucose, (beta-d)-isomer has been researched along with Prediabetes in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.70) | 29.6817 |
| 2010's | 10 (37.04) | 24.3611 |
| 2020's | 16 (59.26) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SH; Cheng, JT; Chung, HH; Ku, PM; Wang, LY; Yu, YM | 1 |
| Karumuthil-Melethil, S; Li, R; Perez, N; Vasu, C | 1 |
| Birkenfeld, AL; Dannecker, C; Fritsche, A; Fritsche, L; Häring, HU; Heni, M; Hummel, J; Kantartzis, K; Kullmann, S; Machann, J; Peter, A; Preissl, H; Stefan, N; Veit, R; Vosseler, A; Wagner, R | 1 |
| Haluzik, M; Hüttl, M; Malinska, H; Markova, I; Miklankova, D; Poruba, M; Vaněčkova, I; Zapletalova, I | 1 |
| Birkenfeld, AL; Dannecker, C; Fritsche, A; Häring, HU; Heni, M; Hummel, J; Kullmann, S; Machann, J; Peter, A; Wagner, R | 1 |
| AlHummiany, B; Allwood-Spiers, S; Berry, C; Brooksbank, KJM; Campbell, RT; Chong, V; Coyle, L; Docherty, KF; Dreisbach, JG; Gillis, KA; Hall Barrientos, P; Jhund, PS; Kuehn, B; Labinjoh, C; Lang, NN; Lee, MMY; Lennie, V; Mangion, K; Mark, PB; McConnachie, A; McMurray, JJV; Murphy, CL; Petrie, CJ; Petrie, JR; Petrie, MC; Radjenovic, A; Roditi, G; Sattar, N; Sharma, K; Sourbron, S; Speirits, IA; Thompson, J; Welsh, P; Wetherall, K; Woodward, R; Wright, A | 1 |
| Espinosa, E; Ferreira-Hermosillo, A; Garrido-Mendoza, AP; Mendoza-Zubieta, V; Mercado, M; Molina-Ayala, MA; Molina-Guerrero, D; Ramírez-Rentería, C | 1 |
| Chen, J; Feng, Y; Guo, H; Li, J; Wang, N; Wang, X; Zeng, J; Zhang, M | 1 |
| Díaz-Cruz, C; Díaz-Cruz, K; González-Ortiz, M; Martínez-Abundis, E; Patiño-Laguna, AJ; Ramírez-Rodríguez, ZG; Rosales-Rivera, LY | 2 |
| Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Dejgaard, TF; Færch, K; Jørgensen, ME; Karstoft, K; Pedersen, C; Persson, F; Ried-Larsen, M; Tvermosegaard, M; Vainø, CTR; Vistisen, D | 1 |
| Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Faerch, K; Holst, JJ; Jørgensen, ME; Karstoft, K; Persson, F; Quist, JS; Ried-Larsen, M; Torekov, SS; Vistisen, D; Wewer Albrechtsen, NJ | 1 |
| Haluzik, M; Huttl, M; Kucera, J; Malinska, H; Markova, I; Miklankova, D; Oliyarnyk, O; Sedlacek, R; Trnovska, J | 1 |
| Calefi, GS; Carrilho, AJF; da Rocha, AF; de Faria, EC; Marquezine, GF; Mazzuco, TL; Morimoto, HK; Pereira Junior, PS; Urbano, MR | 1 |
| Loutradis, C; Sarafidis, PA; Theodorakopoulou, MP | 1 |
| Lang, CC; Singh, JS; Struthers, AD | 1 |
| Jhund, PS; Lee, MMY; McMurray, JJV; Petrie, MC; Sattar, N | 1 |
| Eriksson, JW; Johnsson, E; Katsogiannos, P; Lundkvist, P; Pereira, MJ; Sjöström, CD | 1 |
| Amadid, H; Færch, K; Jørgensen, ME; Karstoft, K; Nielsen, LB; Persson, F; Ried-Larsen, M | 1 |
| Dong, Y; Li, X; Sun, J; Sun, W; Xing, Y; Xiu, Z; Yu, X; Zhang, B; Zhuang, C | 1 |
| Chatsudthipong, V; Chattipakorn, N; Chueakula, N; Jaikumkao, K; Lungkaphin, A; Pongchaidecha, A; Thongnak, LO; Wanchai, K | 1 |
| González-Ortiz, M; Martínez-Abundis, E; Ramírez-Rodríguez, AM | 1 |
| Abdel-Hamid, AAM; Firgany, AEL | 1 |
| Bengtsson, O; DeMets, DL; Inzucchi, SE; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD | 1 |
| Amini, S; Eriksson, JW; Johnsson, E; Lundkvist, P; Pereira, MJ; Sjöström, CD | 1 |
| Hasegawa, Y; Kim-Mitsuyama, S; Koibuchi, N; Kusaka, H; Ogawa, H | 1 |
| Close, KL; Dove, AE; Gao, HX; Marathe, PH; Odeh, SA | 1 |
10 trial(s) available for glucose, (beta-d)-isomer and Prediabetes
| Article | Year |
|---|---|
Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Hypothalamus; Insulin Resistance; Middle Aged; Prediabetic State | 2022 |
Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Mexico; Middle Aged; Obesity, Morbid; Prediabetic State; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome; Waist Circumference; Weight Loss; Young Adult | 2020 |
Effects of dapagliflozin on blood pressure variability in patients with prediabetes and prehypertension without pharmacological treatment: a randomized trial.
Topics: Benzhydryl Compounds; Blood Pressure; Double-Blind Method; Glucosides; Humans; Prediabetic State; Prehypertension | 2020 |
The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Denmark; Exercise; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Overweight; Prediabetic State; Treatment Outcome | 2021 |
No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prediabetic State | 2021 |
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Topics: Adiposity; Anti-Obesity Agents; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Follow-Up Studies; Ghrelin; Glucosides; Humans; Hypoglycemic Agents; Male; Membrane Transport Modulators; Middle Aged; Obesity; Peptides; Prediabetic State; Proof of Concept Study; Risk Factors; Sodium-Glucose Transport Proteins; Sweden; Venoms; Weight Loss | 2017 |
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
Topics: Adult; Aged; Benzhydryl Compounds; Body Composition; Body Weight; Cardiovascular Diseases; Denmark; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Prediabetic State; Research Design; Risk Factors | 2017 |
Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients with Prediabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin; Insulin Resistance; Insulin Secretion; Male; Middle Aged; Placebos; Prediabetic State; Treatment Outcome | 2020 |
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics.
Topics: Aged; Benzhydryl Compounds; Diabetes Complications; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prediabetic State; Reference Values; Registries; Treatment Outcome | 2019 |
Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
Topics: Adipose Tissue; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Double-Blind Method; Drug Therapy, Combination; Exenatide; Female; Glucose Intolerance; Glucosides; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Magnetic Resonance Imaging; Male; Middle Aged; Nausea; Obesity; Peptides; Prediabetic State; Treatment Outcome; Venoms; Weight Loss | 2017 |
17 other study(ies) available for glucose, (beta-d)-isomer and Prediabetes
| Article | Year |
|---|---|
Insulin resistance induced by zymosan as a new animal model in mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diet; Disease Models, Animal; Fructose; Insulin Resistance; Male; Mice; Mice, Inbred BALB C; Prediabetic State; Recovery of Function; Zymosan | 2013 |
Induction of innate immune response through TLR2 and dectin 1 prevents type 1 diabetes.
Topics: Animals; Antigen-Presenting Cells; Cells, Cultured; Coculture Techniques; Crosses, Genetic; Cytokines; Diabetes Mellitus, Type 1; Female; Hyperglycemia; Hyperinsulinism; Immunity, Innate; Lectins, C-Type; Membrane Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Nerve Tissue Proteins; Prediabetic State; Toll-Like Receptor 2; Zymosan | 2008 |
In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia.
Topics: Animals; Benzhydryl Compounds; Cytochrome P-450 Enzyme System; Disease Models, Animal; Disease Progression; Glucosides; Hyperglycemia; Hyperlipoproteinemia Type IV; Inflammation Mediators; Insulin Resistance; Lipid Metabolism; Liver; Male; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Prediabetic State; Rats; Rats, Mutant Strains; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Eight weeks of empagliflozin does not affect pancreatic fat content and insulin secretion in people with prediabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Insulin; Insulin Resistance; Insulin Secretion; Prediabetic State | 2022 |
Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney; Prediabetic State; Stroke Volume | 2022 |
2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside induces autophagy of liver by activating PI3K/Akt and Erk pathway in prediabetic rats.
Topics: Animals; Autophagy; Fallopia multiflora; Glucosides; Liver; Male; MAP Kinase Signaling System; Molecular Structure; Phosphatidylinositol 3-Kinases; Prediabetic State; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Stilbenes | 2020 |
Metabolic cardio- and reno-protective effects of empagliflozin in a prediabetic rat model.
Topics: Animals; Benzhydryl Compounds; Disease Models, Animal; Glucose; Glucosides; Heart; Insulin Resistance; Ketone Bodies; Kidney; Male; Oxidative Stress; Prediabetic State; Protective Agents; Rats; Rats, Wistar | 2020 |
Growth hormone directly favors hepatic ketogenesis in persons with prediabetes or type 2 diabetes mellitus treated with empagliflozin.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Growth Hormone; Humans; Hypoglycemic Agents; Male; Prediabetic State | 2021 |
Dapagliflozin does not affect blood pressure variability in prediabetic prehypertensive subjects.
Topics: Benzhydryl Compounds; Blood Pressure; Glucosides; Humans; Prediabetic State; Prehypertension | 2021 |
Response to Comment on Díaz-Cruz et al. Effect of dapagliflozin on blood pressure variability in patients with prediabetes and prehypertension without pharmacological treatment: a randomized trial Blood Press Monit 2020; 25:346-350.
Topics: Benzhydryl Compounds; Blood Pressure; Glucosides; Humans; Prediabetic State; Prehypertension | 2021 |
Letter by Singh et al Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)".
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Prediabetic State; Stroke Volume | 2021 |
Response by Lee et al to Letter Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)".
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Prediabetic State; Stroke Volume | 2021 |
Oroxin A from Oroxylum indicum prevents the progression from prediabetes to diabetes in streptozotocin and high-fat diet induced mice.
Topics: alpha-Glucosidases; Animals; Antioxidants; Bignoniaceae; Diabetes Mellitus, Experimental; Diet, High-Fat; Flavones; Glucosides; Glycoside Hydrolase Inhibitors; Humans; Lipid Metabolism; Liver; Male; Mice; Oxidative Stress; PPAR gamma; Prediabetic State; Seeds; Streptozocin | 2018 |
Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Disease Progression; Endoplasmic Reticulum Stress; Glucosides; Inflammation; Kidney; Kidney Diseases; Male; Prediabetic State; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Modulatory effect of empagliflozin on cellular parameters of endocrine pancreas in experimental pre-diabetes.
Topics: Animals; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Caspase 3; Cell Proliferation; Cytokines; Diabetes Mellitus, Experimental; Glucagon; Glucagon-Secreting Cells; Glucose Tolerance Test; Glucosides; Homeostasis; Immunohistochemistry; Insulin-Secreting Cells; Islets of Langerhans; Male; Prediabetic State; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.
Topics: Adipocytes, White; Adiposity; Animals; Benzhydryl Compounds; Biomarkers; Cardiomegaly; Disease Models, Animal; Diuresis; Glucosides; Hemodynamics; Hypertrophy; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Metabolic Syndrome; Oxidative Stress; Prediabetic State; Rats, Inbred SHR; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Water-Electrolyte Balance; Weight Gain | 2016 |
Obesity Week 2016 Annual Meeting.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Congresses as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Prediabetic State; Quality of Life; Treatment Outcome; Weight Loss | 2017 |